Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:29:29 EDT Fri 09 May 2025
Enter Symbol
or Name
USA
CA



Q:BEAM - BEAM THERAPEUTICS INC - https://beamtx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BEAM - Q0.517.25·18.000.817.25+1.0256.33,148.752,19926,31816.26  17.75  15.6435.25  13.525May 08May 0615 min RT 2¢

Recent Trades - Last 10 of 26318
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-06 07:00U:BEAMNews ReleaseBeam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
2025-04-05 07:00U:BEAMNews ReleaseBeam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
2025-03-27 16:01U:BEAMNews ReleaseBeam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
2025-03-10 06:01U:BEAMNews ReleaseBeam Therapeutics Announces Pricing of Underwritten Offering
2025-03-10 06:00U:BEAMNews ReleaseBeam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
2025-02-25 07:00U:BEAMNews ReleaseBeam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
2025-02-24 07:00U:BEAMNews ReleaseBeam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
2025-01-30 07:00U:BEAMNews ReleaseBeam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
2025-01-23 07:00U:BEAMNews ReleaseBeam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
2025-01-13 07:00U:BEAMNews ReleaseBeam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
2024-12-17 07:00U:BEAMNews ReleaseBeam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-08 13:45U:BEAMNews ReleaseBeam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
2024-12-07 11:30U:BEAMNews ReleaseBeam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
2024-12-06 07:00U:BEAMNews ReleaseBeam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
2024-12-04 07:00U:BEAMNews ReleaseBeam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
2024-11-12 16:01U:BEAMNews ReleaseBeam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
2024-11-05 09:00U:BEAMNews ReleaseBeam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
2024-11-05 06:30U:BEAMNews ReleaseBeam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
2024-10-29 06:30U:BEAMNews ReleaseBeam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
2024-08-06 06:30U:BEAMNews ReleaseBeam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results